Funded Tech Companies

Olema Oncology

Wondering who provided funding to Olema Oncology? OrbiMed, BVF Partners and BlackRock joined the equity holders in this biopharmaceutical company.

Company Overview

Contact Information

Company Background Information

Overview

Olema Oncology (Nasdaq: OLMA) is a biopharmaceutical company developing innovative targeted therapies for women's cancers. The Company's lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

11/18/2020

Financing History

Management Team

Title

Name

Email & Social

Chief Executive Officer

Sean Bohen

        

Chief Medical Officer

Pamela Klein

        

Chief Operating Officer

Shane Kovacs

        

Chief Scientific Officer

Peter Kushner

        

Chief Technical Officer

Cyrus Harmon

        

VP - Bus. Development

Kinney Horn

        

VP - Bus. Development

David Myles

        

VP - General Counsel

John Moriarty

        

Company Investors

• OrbiMed
• BVF Partners
• BlackRock
• Deerfield Capital
• Vivo Capital (Albert Cha)
• venBio
• Wellington Management Company
• Venrock
• Foresite Capital
• Logos Capital (Graham Walmsley)
• RA Capital
• Cormorant Asset Management
• Janus Henderson Investors
• Surveyor Capital

Browse more funded tech companies:

Olea Edge Analytics | OLEO

Share this article

About Our VC Deals Database

This venture capital transaction data comes via a partnership with VentureDeal.com, a leading provider of venture capital transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary